Nothing Special   »   [go: up one dir, main page]

TN2009000028A1 - Agonistes de ep2 - Google Patents

Agonistes de ep2

Info

Publication number
TN2009000028A1
TN2009000028A1 TN2009000028A TN2009000028A TN2009000028A1 TN 2009000028 A1 TN2009000028 A1 TN 2009000028A1 TN 2009000028 A TN2009000028 A TN 2009000028A TN 2009000028 A TN2009000028 A TN 2009000028A TN 2009000028 A1 TN2009000028 A1 TN 2009000028A1
Authority
TN
Tunisia
Prior art keywords
agonists
compounds
processes
preparation
methods
Prior art date
Application number
TN2009000028A
Other languages
English (en)
Inventor
Ganesh Prasanna
Charles Floyd Bosworth
Fontaine Jennifer Anne La
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TN2009000028A1 publication Critical patent/TN2009000028A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention propose des agonistes de EP2 des procédés pour leur préparation, des compositions pharmaceutiques contenant ces composés, et des méthodes d'utilisation de ces composés et compositions pour abaisser la pression intraoculaire et traiter ainsi Ie glaucome.
TN2009000028A 2006-07-28 2009-01-26 Agonistes de ep2 TN2009000028A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83390706P 2006-07-28 2006-07-28
US94192307P 2007-06-04 2007-06-04
PCT/IB2007/002044 WO2008015517A2 (fr) 2006-07-28 2007-07-16 Agonistes de ep2

Publications (1)

Publication Number Publication Date
TN2009000028A1 true TN2009000028A1 (fr) 2010-08-19

Family

ID=38896126

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000028A TN2009000028A1 (fr) 2006-07-28 2009-01-26 Agonistes de ep2

Country Status (26)

Country Link
US (2) US7622475B2 (fr)
EP (1) EP2059507B1 (fr)
JP (1) JP4583500B2 (fr)
KR (1) KR101088942B1 (fr)
AP (1) AP2009004754A0 (fr)
AR (1) AR062122A1 (fr)
AU (1) AU2007280130B2 (fr)
BR (1) BRPI0714683A2 (fr)
CA (1) CA2659184C (fr)
CL (1) CL2007002207A1 (fr)
CR (1) CR10554A (fr)
EA (1) EA200970067A1 (fr)
EC (1) ECSP099071A (fr)
GT (1) GT200700064A (fr)
HK (1) HK1133876A1 (fr)
IL (1) IL196355A0 (fr)
MA (1) MA30604B1 (fr)
MX (1) MX2009001062A (fr)
NO (1) NO20090738L (fr)
NZ (1) NZ573964A (fr)
PE (1) PE20080408A1 (fr)
RS (1) RS20090002A (fr)
TN (1) TN2009000028A1 (fr)
TW (1) TWI372757B (fr)
UY (1) UY30511A1 (fr)
WO (1) WO2008015517A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201904655T4 (tr) * 2008-03-12 2019-06-21 Ube Industries Piridilaminoasetik asit bileşiği.
EP2415763B1 (fr) 2009-03-30 2016-01-27 Ube Industries, Ltd. Composition pharmaceutique pour la prévention ou le traitement du glaucome
WO2011030865A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques substitués
CA2773997A1 (fr) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Composes aniline
CA2773998A1 (fr) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Composes carbonyle substitues
WO2011030872A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés sulfonamide
WO2011030873A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques
WO2011030871A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés hétéroaryle n-substitués
KR20120101722A (ko) * 2009-12-25 2012-09-14 우베 고산 가부시키가이샤 아미노피리딘 화합물
KR20140003395A (ko) * 2010-08-17 2014-01-09 알러간, 인코포레이티드 각막 혼탁 치료용 ep2 또는 ep4 항진제들
SG11201400555SA (en) 2011-09-16 2014-04-28 Fovea Pharmaceuticals Aniline derivatives,their preparation and their therapeutic application
WO2013109991A1 (fr) * 2012-01-20 2013-07-25 Acucela Inc. Composés hétérocycliques substitués pour le traitement d'une maladie
CN104507906B (zh) 2012-05-03 2017-04-12 塔科达有限责任公司 新的ep2受体激动剂
US9339496B2 (en) 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
US9676720B2 (en) * 2013-03-28 2017-06-13 Ube Industries, Ltd. Substituted biaryl compound
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
AR105215A1 (es) * 2015-07-01 2017-09-13 Santen Pharmaceutical Co Ltd Formulación de depósito que contiene ésteres de ácido cítrico

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1000619A3 (fr) * 1998-06-23 2002-07-24 Pfizer Products Inc. Méthode de traitement du glaucome
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
US20020115695A1 (en) * 2000-11-07 2002-08-22 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
JP2005513030A (ja) 2001-11-30 2005-05-12 ファイザー・プロダクツ・インク 医薬組成物及びｅｐ２受容体選択的アゴニストの投与方法
KR20040077884A (ko) * 2002-01-31 2004-09-07 화이자 프로덕츠 인코포레이티드 （3-｛〔（4-3급-뷰틸-벤질）-（피리딘-3-설폰일）-아미노〕-메틸｝-페녹시）-아세트산의 대사산물
KR20050105511A (ko) 2003-03-04 2005-11-04 화이자 프로덕츠 인크. 의학적 치료에서 ｅｐ2 선택적 수용체 효능제의 용도
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma

Also Published As

Publication number Publication date
EP2059507A2 (fr) 2009-05-20
KR20090023507A (ko) 2009-03-04
US20100105905A1 (en) 2010-04-29
EA200970067A1 (ru) 2009-08-28
UY30511A1 (es) 2008-02-29
MX2009001062A (es) 2009-02-06
GT200700064A (es) 2009-06-18
ECSP099071A (es) 2009-02-27
CL2007002207A1 (es) 2008-02-01
CA2659184A1 (fr) 2008-02-07
AU2007280130A1 (en) 2008-02-07
NZ573964A (en) 2010-11-26
US7622475B2 (en) 2009-11-24
WO2008015517A3 (fr) 2008-06-12
IL196355A0 (en) 2009-09-22
WO2008015517A2 (fr) 2008-02-07
KR101088942B1 (ko) 2011-12-01
EP2059507B1 (fr) 2013-03-20
TWI372757B (en) 2012-09-21
TW200817360A (en) 2008-04-16
AU2007280130B2 (en) 2011-09-22
CA2659184C (fr) 2012-02-21
BRPI0714683A2 (pt) 2013-03-26
JP2009544751A (ja) 2009-12-17
NO20090738L (no) 2009-04-27
CR10554A (es) 2009-02-10
AR062122A1 (es) 2008-10-15
AP2009004754A0 (en) 2009-02-28
HK1133876A1 (en) 2010-04-09
PE20080408A1 (es) 2008-04-28
MA30604B1 (fr) 2009-07-01
US20080045545A1 (en) 2008-02-21
JP4583500B2 (ja) 2010-11-17
RS20090002A (en) 2010-06-30

Similar Documents

Publication Publication Date Title
TN2009000028A1 (fr) Agonistes de ep2
MA35576B1 (fr) Nouveaux composés
TN2011000454A1 (fr) Derives de benzofurannyle utilises comme inhibiteurs de glucokinase
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA29791B1 (fr) Composes therapeutiques.
MA31419B1 (fr) Derives de pyridine
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA31953B1 (fr) Nouveaux derives du thiophene.
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA34599B1 (fr) Compositions pharmaceutiques contenant un inhibiteur dgat1
MA30629B1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
MA35638B1 (fr) 2-thiopyrimidinones
MA49127B1 (fr) Dérivés d'indole n-substitués
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
MA32506B1 (fr) Nouveaux composes